Your email has been successfully added to our mailing list.

×
0 -0.000262467191600998 -0.000918635170603585 -0.00124671916010497 -0.00196850393700795 -0.000984251968503974 -0.00137795275590556 -0.00183727034120736
Stock impact report

Health Canada Approves ZOLADEX® LA for the Management of Estrogen Receptor-Positive (ER+) Early Breast Cancer with a High Risk of Recurrence or Advanced Breast Cancer in Pre- and Perimenop...

AstraZeneca PLC - American Depositary Shares (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
Company Research Source: Yahoo! Finance
for ZOLADEX LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women. While the monthly dose of ZOLADEX (3.6mg) has been approved for use in breast cancer since 1995, this recent approval provides a 3-month dosing option for young women with hormone-positive (HR+) breast cancer. "For young women with hormone sensitive breast cancer, suppression of ovarian function is a core component of their treatment plan to prevent recurrence," said Nathalie LeVasseur, MD, FRCPC, Assistant Clinical Professor, Division of Medical Oncology at the University of British Columbia in Vancouver. "I am pleased to see ZOLADEX LA is now available as a 3-month dosing option for premenopausal women with ER+ breast cancer." Every year, approximately 5,000 young Canadian women are diagnosed with breast cancer. Breast cancer is the leading cause of cancer dea Show less Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AZN alerts
Opt-in for
AZN alerts

from News Quantified
Opt-in for
AZN alerts

from News Quantified